Background and aims Hepatocellular carcinoma (HCC) is one of the most common
malignancies in the world and the sixth leading cause of cancer death worldwide, and it is …

Lenvatinib (LVN) is a potentially effective multiple-targeted receptor tyrosine kinase inhibitor
approved for treating hepatocellular carcinoma, metastatic renal cell carcinoma and thyroid …

We herein report the identification, structural optimization, and structure–activity relationship
of thieno [2, 3-d] pyrimidine derivatives as a novel kind of selective vascular endothelial …

Liver disease represents an increasing cause of global morbidity and mortality. Currently,
liver transplant is the only treatment curative for end-stage liver disease. Donor organs …

Multidrug resistance is one of the reasons for low survival of advanced hepatocellular
carcinoma (HCC). Our previous studies indicate that the hedgehog signalling is involved in …

Lenvatinib (LEN) combined with immune checkpoint PD-1 blockade is among the most
effective treatment strategies for advanced hepatocellular carcinoma (HCC) and has been …

Introduction Hepatocellular carcinoma (HCC) is the fifth malignancy in terms of frequency
and the fourth malignancy in terms of cancer-related death worldwide. Systemic therapy of …

Prior studies from our group have combined the multi-kinase inhibitor sorafenib with HDAC
inhibitors in GI tumor cells that resulted in the trials NCT02349867 and NCT01075113. The …

Lenvatinib mesylate (LEN) is a new generation anti-cancer medication included under the
class of multiple kinase inhibitor and approved for the treatment of differentiated thyroid …

The clinical efficacy of lenvatinib (LFT) is limited by its poor aqueous solubility and low
bioavailability. In this work, LFT-loaded soy phospholipid and sodium glycocholate mixed …